2024-11-09 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

This report analyzes Johnson & Johnson (JNJ), a global healthcare company specializing in pharmaceuticals, medical devices, and consumer healthcare products.

### 1. Performance Analysis:

* **Cumulative Return:** JNJ has a cumulative return of 30.65%, significantly lower than the S&P 500 (VOO) which has a cumulative return of 141.71%.
* **Performance Gap:** JNJ is currently lagging behind the S&P 500 by -111.06%, which represents the 0% percentile of the historical gap between JNJ and the S&P 500. 
* **Alpha & Beta Analysis:** JNJ's alpha, a measure of its outperformance relative to the market, has been volatile in recent years, ranging from -55.9% to 3.8%. Its beta, a measure of its volatility relative to the market, has generally been below 1, indicating it is less volatile than the overall market.

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 33.7% | 10.1% | 3.5% | 0.7 |
| 2016-2018 | 28.4% | 17.5% | 3.8% | 0.7 |
| 2017-2019 | 25.9% | 17.5% | -17.1% | 0.7 |
| 2018-2020 | 13.0% | 27.5% | -26.1% | 0.7 |
| 2019-2021 | 33.9% | 27.5% | -55.9% | 0.6 |
| 2020-2022 | 21.0% | 27.5% | 3.3% | 0.5 |
| 2021-2023 | 0.1% | 16.6% | -28.7% | 0.3 |
| 2022-2024 | -8.6% | 16.6% | -33.3% | 0.2 |

**Conclusion:** JNJ has consistently underperformed the S&P 500 in recent years, with its Alpha being negative for the past 5 years. This suggests that JNJ's stock price has not kept pace with the broader market's growth.

### 2. Recent Price Movement:

* **Closing Price:** $156.73
* **Last Market Price:** $156.02
* **5-day Moving Average:** $158.27
* **20-day Moving Average:** $161.56
* **60-day Moving Average:** $162.61

**Conclusion:** JNJ's stock price is currently trading below its 5, 20, and 60-day moving averages, indicating a downtrend. 

### 3. Technical Indicators:

* **RSI:** 26.29 (Below 30 indicates oversold territory)
* **PPO:** -0.36 (Negative value suggests downward momentum)
* **Delta_Previous_Relative_Divergence:** -4.42 (Short-term downward trend)

**Conclusion:** Technical indicators suggest that JNJ is currently oversold and experiencing downward momentum. 

### 4. Recent Earnings & Outlook:

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

**Conclusion:** While JNJ's recent revenue has remained stable, EPS has been volatile. The most recent earnings report on October 23, 2024, revealed an EPS of 1.12, which was lower than expected.

### 5. Financial Information:

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

**Conclusion:** JNJ maintains a consistent and high profit margin, indicating strong profitability. ROE has shown some fluctuations, but overall remains healthy, signifying effective use of shareholder equity.

### 6. News & Recent Issues:

* **Recent Earnings News:**  Analyze recent earnings news from reliable sources like Shacknews, financial news websites, or press releases from JNJ.
* **Recent Market Outlook:** Research analyst opinions and market sentiment on JNJ using platforms like Finbold, Yahoo Finance, or Seeking Alpha. 
* **Performance Highlights:** Identify any recent significant events, announcements, or developments impacting JNJ's performance.

### 7. Overall Analysis:

JNJ is a mature, dividend-paying company with a strong track record of consistent revenue and profitability. However, its recent performance has lagged behind the broader market, and technical indicators suggest a short-term downtrend. 

While JNJ's financials remain strong, its future performance depends on a number of factors, including:

* **Competition in the healthcare industry:** JNJ faces fierce competition in all three of its major segments. 
* **Regulatory environment:** Healthcare regulations can impact JNJ's operations and product development.
* **Economic conditions:** The global economy can influence consumer demand for healthcare products.

Based on the current analysis, investors may want to consider JNJ as a long-term investment with a focus on its dividend yield and potential for growth in emerging markets. However, it is important to monitor the company's performance and track its progress against its competition. 
